Lung Cancer Trials Ask AI to find trials
TerminatedPhase 2NCT00372073
Official study title

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

Study summary

A phase 2 study to evaluate efficacy of oral seliciclib in treating non-small cell lung cancer (NSCLC).

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedseliciclib and placebo

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Dec 22, 2021 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?20 U.S. locations

Locations may change over time.

Who runs it?Cyclacel Pharmaceuticals, Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
Cyclacel Pharmaceuticals, Inc.
Interventions being studied
Drug: seliciclib; Drug: placebo
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Adult patients with histologically-confirmed recurrent non-small cell lung cancer have had at least two prior systemic treatment regimens
  • Must have measurable disease according to RECIST
  • Eastern Cooperative Oncology Group performance status 0-1
  • Adequate bone marrow, hepatic and renal function
  • Ability to swallow capsules
  • At least 3 weeks from prior systemic treatments including investigational anti-cancer therapy, at least 7 days from prior radiation therapy and have recovered from prior toxicities
  • At least 3 weeks from major surgery
Reasons someone may not be able to joinExclusion criteria
  • Non-small cell cancer histology contains a component of small cell lung cancer
  • Previously untreated CNS metastasis or progressive CNS metastasis
  • Prior treatment with a CDK inhibitor
  • Currently receiving radiotherapy, biological therapy, or any other investigational therapy
  • Uncontrolled intercurrent illness
  • Having other cancers that have been treated with chemotherapy or biological therapy in the past 5 years with the exception of adequately treated in situ cervical cancer or basal cell skin cancer
  • Pregnant or lactating women
  • Known to be HIV-positive
  • Active hepatitis B and/or hepatitis C infection

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Arizona Cancer CenterTucson, Arizona
  • Pacific Coast Hematology Oncology GroupFountain Valley, California
  • Pasco Hernando OncologyNew Port Richey, Florida
  • Rush University Medical CenterChicago, Illinois
  • The University of ChicagoChicago, Illinois
  • University of Maryland, Greenebaun Cancer CenterBaltimore, Maryland
  • Dana Farber Cancer InstituteBoston, Massachusetts
  • Nebraska Medical CenterOmaha, Nebraska
  • Nevada Cancer Research FoundationLas Vegas, Nevada
  • VA Sierra Nevada Health Care SystemReno, Nevada
  • New Mexico Oncology Hematology ConsultantsAlbuquerque, New Mexico
  • Columbia Presbyterian Medical CenterNew York, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 22, 2021. Always confirm current availability with the study team.

View original record ↗